Gilgamesh Pharmaceuticals
Series B in 2022
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.
Sensorium Therapeutics
Venture Round in 2022
Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.
Cordance Medical
Seed Round in 2022
Cordance Medical is a medical device company focused on innovative therapies for central nervous system (CNS) conditions, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has developed a non-invasive ultrasound system specifically designed to open the blood-brain barrier. This low-power ultrasound technology allows for precise and reversible openings of the blood-brain barrier, facilitating targeted delivery of systemically administered medications to specific brain regions. By enhancing access to the brain for therapeutic agents, Cordance Medical aims to create new diagnostic and treatment options for patients suffering from various CNS pathologies.
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.
Blackrock Neurotech
Convertible Note in 2021
Blackrock Neurotech is a company dedicated to developing advanced neurotechnology platforms designed to record bio-potentials from both the central and peripheral nervous systems for chronic and acute applications. The company's precision electrode technology is pivotal in numerous global innovations related to brain-computer interfaces (BCI) and neural signal processing and stimulation. Blackrock Neurotech aims to assist individuals with disabilities, enabling them to walk, talk, see, hear, and feel by providing the clinical community with innovative tools and expertise to create novel implantable solutions that enhance human lives.
Kadence Bio
Pre Seed Round in 2021
Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent historically utilized by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is formulated from alkaloids found in kanna. This candidate is designed to enhance mood and performance in males, offering potential for affordable treatment options. Kanna Health's mission centers on leveraging the traditional use of kanna to create modern therapeutic solutions that improve health outcomes.
Ceretype Neuromedicine
Convertible Note in 2021
Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.
Ksana Health
Seed Round in 2021
Ksana Health, founded in 2019 and based in Eugene, Oregon, is a developer of a digital mental health platform that aims to enhance mental health outcomes through personalized behavioral insights and timely interventions. The company's platform enables the collection of mental health data from users, which is then seamlessly transferred to healthcare practitioners via an app. By providing passive and continuous remote patient monitoring alongside digital therapeutics, Ksana Health seeks to support individuals in managing their mental health effectively.
Appia Bio
Series A in 2021
Appia Bio is a biotechnology company dedicated to the research and development of off-the-shelf allogeneic cell therapies, with a particular focus on engineered allogeneic cell therapies for various medical indications. The company utilizes its proprietary ACUA technology platform to harness the biology of lymphocyte development, integrating chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering. This innovative approach allows Appia Bio to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes derived from hematopoietic stem cells (HSCs). By maturing and scaling healthy stem cells into invariant T-cell therapies, Appia Bio aims to provide physicians with safe and targeted cancer treatment options, thereby expanding patient access to advanced therapeutic solutions.
Eikon Therapeutics
Series A in 2021
Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Established in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By directly measuring the interactions of chemical compounds with individual proteins within a live cellular environment, Eikon Therapeutics enhances the understanding of biological processes and supports the development of targeted therapies. The integration of biology, engineering, and chemistry in its proprietary platforms allows Eikon Therapeutics to streamline the drug discovery process, advance clinical programs, and expand its pipeline of potential medications.
OccamzRazor
Convertible Note in 2021
OccamzRazor is a biotechnology company that leverages machine learning and advanced biological techniques to enhance drug discovery and development processes. The company employs two proprietary technologies: Panoramic AI and RazorBrain. These tools work together to extract data from unstructured text sources, such as publications and patient-reported outcomes, and integrate it with structured data like genomics, proteomics, and phenomics. This integration aims to generate robust hypotheses for drug discovery and provide valuable insights into therapeutic strategies. OccamzRazor's applications include extracting and curating biomedical text data, identifying novel targets, and repurposing existing drugs. The company is particularly focused on developing neuroscience therapeutics, with a notable emphasis on Parkinson's Disease.
Sana Health
Seed Round in 2020
Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.
Delix Therapeutics
Convertible Note in 2020
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.
Enable Medicine
Venture Round in 2020
Enable Medicine is a biotechnology company founded in 2019 by Aaron Mayer and Sunil Bodapati in Menlo Park, California. The company specializes in a bio-computational platform that facilitates the extraction of insights from diverse biological samples. Its Enable Cloud Platform offers a collaborative ecosystem equipped with tools for generating, visualizing, and analyzing various biological image formats. By providing end-to-end services that include custom panel development, data acquisition through advanced imaging technology, and spatial data analysis, Enable Medicine supports researchers, drug developers, and physicians in creating cellular maps that enhance drug discovery processes. The platform aims to reduce costs and accelerate the time required to achieve scientific insights.
Perception Neuroscience
Convertible Note in 2020
Perception Neuroscience is a biopharmaceutical company dedicated to creating innovative therapies for neuropsychiatric conditions. The company's primary focus is on developing arketamine, an NMDA antagonist designed to offer effective treatment for serious psychiatric disorders. Arketamine has shown promise for its rapid-acting antidepressant properties and potential anti-suicidal effects, positioning the company at the forefront of advancing mental health treatment solutions.
Multidisciplinary Association for Psychedelic Studies
Funding Round in 2020
MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. The organization is focused on developing psychedelics and marijuana into prescription medicines, training therapists and working to establish a network of treatment centers, supporting scientific research into spirituality, creativity, and neuroscience, and educating the public honestly about the risks and benefits of psychedelics and marijuana. MAPS was founded in 1986 by Rick Doblin and is headquartered in Santa Cruz, California.
OpenBiome
Seed Round in 2020
OpenBiome is a nonprofit organization dedicated to expanding safe access to fecal microbiota transplants (FMT), and to catalyzing research into the human microbiome. Founded by a team of doctors, scientists and public health advocates, OpenBiome has two primary objectives.
Alto Neuroscience
Seed Round in 2020
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.
Cambrian Biopharma
Series A in 2019
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
ATAI Life Sciences
Secondary Market in 2019
ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.
COMPASS Pathways
Convertible Note in 2019
COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.
Psy Therapeutics
Seed Round in 2019
Psy Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative therapies for central nervous system (CNS) disorders. The company specializes in addressing conditions such as anxiety, depression, and dementia, aiming to enhance neuropsychiatric care. Psy Therapeutics employs a research strategy that focuses on identifying effective drug targets and utilizes advanced screening platforms to facilitate the development of its therapeutic candidates. By leveraging a flexible approach to research and development, the company seeks to provide healthcare professionals with effective treatment options that address critical CNS disorders.